GlassScriptPhysician profile
Christopher William Ritchie
NPI 1295393098
$5,314.98
in general payments reported to CMS, 2019-2025
33 companies · $2,053 in 2025
The $2,053 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.29 · 2021: $117 · 2022: $491 · 2023: $900 · 2024: $1,718 · 2025: $2,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,261 · Travel and Lodging: $410.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,261.23 |
| Travel and Lodging | $409.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,449.29 | 2021-2025 | Ams 700, Advance Xp, General - Erectile Dysfunction |
| Medtronic, INC. | $724.48 | 2023-2025 | Interstim |
| Procept Biorobotics Corporation | $418.68 | 2023-2025 | Aquabeam Robotic System |
| Urogen Pharma, INC. | $376.57 | 2024-2025 | |
| Axonics, INC. | $347.72 | 2021-2024 | Axonics |
| Sumitomo Pharma America, INC. | $336.36 | 2024-2025 | Gemtesa, Orgovyx |
| Endo USA, INC. | $210.64 | 2024-2025 | Xiaflex, Aveed |
| Endo Pharmaceuticals INC. | $137.55 | 2023 | Xiaflex |
| Calyxo, INC. | $125.51 | 2025 | Cvac Aspiration System |
| Myriad Genetic Laboratories, INC. | $120.60 | 2024 | Prolaris |
| Ferring Pharmaceuticals INC. | $96.10 | 2025 | Adstiladrin |
| Pfizer INC. | $93.72 | 2025 | |
| Bioprotect Medical, INC. | $87.22 | 2024-2025 | Bioprotect Balloon Implant System |
| C. R. Bard, INC. & Subsidiaries | $83.11 | 2025 | Bard Urinary Drainage Bag, Magic3 Go Intermittent Urinary Catheter |
| Coloplast Corp | $82.14 | 2024-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Laborie Medical Technologies Corp. | $65.78 | 2025 | Optilume Bph Drug Coated Balloon Catheter, Eclipse, Esense 7fr Abdominal Catheter |
| Tolmar, INC. | $58.89 | 2025 | Jatenzo, Eligard |
| Abc Home Medical Supply, INC. | $58.69 | 2025 | |
| Teleflex LLC | $46.71 | 2022-2024 | |
| Progenics Pharmaceuticals, INC. | $44.26 | 2024-2025 | |
| Janssen Biotech, INC. | $42.70 | 2024-2025 | Erleada |
| Karl Storz Endoscopy-America | $36.29 | 2020 | |
| Photocure INC | $33.03 | 2025 | Cysview |
| Urovant Sciences INC | $32.18 | 2021-2022 | |
| Abbvie INC. | $29.92 | 2024-2025 | |
| Olympus America INC. | $28.94 | 2025 | Itind System |
| Dendreon Pharmaceuticals LLC | $26.97 | 2024 | Provenge |
| Smith+Nephew, INC. | $24.58 | 2025 | Stravix Pl |
| Merck Sharp & Dohme LLC | $22.62 | 2024 | Keytruda |
| Ambu INC. | $22.20 | 2024 | |
| Verity Pharmaceuticals INC. | $18.15 | 2025 | Trelstar |
| Sanara Medtech INC. | $17.69 | 2025 | Celleraterx |
| Civco Medical Instruments | $15.69 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ritchie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.